miércoles, 18 de enero de 2017
FDA Approves Rucaparib for BRCA-Positive Ovarian Cancer - Cancer Currents Blog
FDA Approves Rucaparib for Some Women with Advanced Ovarian Cancer - National Cancer Institute
On December 19, the Food and Drug Administration (FDA) granted accelerated approval for rucaparib (Rubraca™) to treat some women with advanced ovarian cancer. The drug is approved for women whose cancers have progressed despite treatment with two or more chemotherapies and whose tumors have a mutation in the BRCA1 or BRCA2 genes, as identified by an FDA-approved companion diagnostic test. About 15% to 20% of ovarian cancers harbor a BRCA mutation.